Current Research Studies

IMPACT: Immunotherapy for Solid Tumor Malignancies in Pediatrics using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T cells

IMPACT - CAR T

  • Condition(s): Soft Tissue, Liver, Kidney
  • Phase: I
  • Clinicaltrials.gov ID: NCT07148050

What is the goal of the study?

The overall goal of this Phase 1 clinical trial is to evaluate the safety of autologous glypican-3 specific chimeric antigen expressing T cells co-expressing IL-15 and IL-21 (SC-CAR.GPC3xIL15.21) in children and young adults with GPC3-positive solid tumors after lymphodepleting chemotherapy.

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team: